| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 371.1 | 377.4 |
| Gross profit | 85.2 | 74.7 |
| Profit before tax | 26.0 | 16.6 |
| Net income | 18.7 | 9.8 |
| EPS (diluted, $ a share) | $0.29 | $0.15 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +90.3% |
|---|---|
| Revenue, year on year | -1.7% |
| Gross margin | 23.0% |
| Operating margin | 6.8% |
10-Q filed with the SEC, NYSE: GRDN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Guardian Pharmacy Services, Inc.: key numbers
- Share price
- $49.43Close, Nov 16
- Sector
- Trade & Services
- Industry
- Retail-Drug Stores and Proprietary StoresSIC 5912
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Guardian Pharmacy Services, Inc.
All →Guardian Pharmacy Services Financial Results
Guardian Pharmacy Services reported Q3 2026 financial results with revenue of $371.1 million and net income of $19.1 million. The company raised its full-year 2026 guidance for both revenue and Adjusted EBITDA, citing strong organic growth in residents served and successful integration of recent acquisitions.
- Term
- Q3 2026
“We are very pleased with our third-quarter performance, highlighted by strong resident and prescription growth. Absent the price reductions from the IRA, revenues would have been up high single digits compared to the third quarter of 2025, mostly driven by organic growth.”
Fred Burke, President and Chief Executive Officer
“With favorable industry fundamentals, a substantial runway for growth, and a liquid balance sheet, we believe Guardian is well positioned to generate durable growth and attractive long-term returns for shareholders.”
Fred Burke, President and Chief Executive Officer